Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare PBM Restrictions Would Lead To Higher Premiums, CBO Says

Executive Summary

The PBM "transparency" provision in the Senate's Medicare prescription drug bill would lead to higher monthly premiums and higher beneficiary cost-sharing, the Congressional Budget Office said
Advertisement

Related Content

PBMs Take Aim At Disclosure, Transparency Provisions In House Health Reform Bill
PBMs Estimate Costs Of Restrictive Legislation; NCPA Urges “Education”
USP To Help Set Formulary Rules Under Medicare Rx Bill
CMS Expected To Delay AWP Regulation; Medicare Conferees Want Credit
PBMs Sue Over Maine Law; Seek Constitutional Protection For Rebates
NACDS Medicare Rx Message: Keep Plan Design Simple
PBM, Chain Drug Summer Lobbying Focuses On Mail-Order Rx In Medicare
FDA Generic Rx Reforms Contribute To Medicare Budget Squeeze
PBM Fees Under Medicare Would Be Reported To DoJ, HHS In Senate Bill
PBM Fees Under Medicare Would Be Reported To DoJ, HHS In Senate Bill
Advertisement
UsernamePublicRestriction

Register

PS042202

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel